GLP1R and acute coronary syndrome: This was further demonstrated in the results of the ELIXA trial evaluating the cardiovascular effects of lixisenatide, a short‐acting GLP‐1 RA, in patients with type 2 diabetes and a recent episode of acute coronary syndrome.